AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca’s coronavirus vaccine could still be ready this year even though it had to halt a key clinical study after a participant got sick, CEO Pascal Soriot said Thursday. The British pharmaceutical firm should know by the end of 2020 whether the vaccine protects patients from the virus if it’s able to resume the study.

AstraZeneca COVID-19 vaccine could be ready this year despite study halt

WHO Chief Scientist Dr. Soumya Swaminathan said Thursday there's no need to be "overly discouraged" by the news, adding that "these things happen.

WHO calls delay in AstraZeneca coronavirus vaccine trial a 'wake up call'

The vaccine’s trials were suspended earlier this week after one of the participants fell severely ill.

AstraZeneca Vaccine Could Be Ready For Approval By Year-End If Trials Resume Soon, CEO Says

Moderna

Pfizer

The pause in AstraZeneca's (AZN) voluntary coronavirus study following an adverse event provides its competitors a breather.

Pausing of AstraZeneca's Coronavirus Study Aids Pfizer, Moderna

The participant in AstraZeneca's AZN, -1.95% AZN, -0.51% Phase 3 study of its experimental COVID-19 vaccine who trigged the clinical trial's hold reportedly was diagnosed with transverse myelitis, which is a spinal disorder potentially associated with vaccines, according to RBC Capital Markets' Brian Abrahams.

Analyst: Vaccines can sometimes trigger rare disorder reportedly identified in AstraZeneca trial

Here's what you need to know about the coronavirus vaccine candidate that was closest to the finish line.

What's Next for AstraZeneca's Coronavirus Vaccine Candidate?

AstraZeneca should still know before the end of the year whether its experimental vaccine protects people against Covid-19, the drugmaker's chief executive Pascal Soriot said on Thursday, as long as it can resume trials soon.

AstraZeneca should know by year-end whether vaccine works if trials restart

AstraZeneca Plc (NYSE: AZN) CEO Pascal Soriot said during a conference call with investors Wednesday that a person experiencing symptoms related to a rare neurological disorder caused its global COVID-19 vaccine trials to pause, Stat reported.

AstraZeneca COVID-19 Vaccine Trial Volunteer Showed Symptoms Of Rare Neurological Disorder

AstraZeneca has been considered to be a global leader in the race to develop a COVID-19 vaccine.

China Drug Maker’s Shares Plunge On AstraZeneca Vaccine “Pause”

Moderna Inc (NASDAQ: MRNA) shares, which shed over 13% Tuesday on an analyst downgrade, are reversing course — with a competitor's clinical woes as the catalyst.

AstraZeneca's Coronavirus Vaccine Setback 'Mixed Blessing' For Moderna: Analyst

The participant who triggered a global shutdown of AstraZeneca's Phase 3 Covid-19 vaccine trials was a woman in the United Kingdom who experienced neurological symptoms consistent with a rare but serious spinal inflammatory disorder called transverse myelitis.

Covid-19 vaccine trial participant had serious neurological symptoms, but could be discharged today, AstraZeneca CEO says

Coronavirus vaccine developer AstraZeneca plc (NYSE: AZN) said Tuesday that a Phase 3 trial being conducted with Oxford University has been put on hold for a safety review.

Why AstraZeneca's Coronavirus Trial Halt May Not Be As Bad As It Sounds

The London-listed firm had to pause global trials of its potential vaccine for COVID-19 after an unexplained illness in a participant, which sent its shares lower as the move was seen as dimming prospects for an early rollout.

AstraZeneca may resume COVID-19 vaccine trials next week: FT

AstraZeneca AZN, -0.11% AZN, +0.25% may resume its halted trial of its COVID-19 vaccine as early as next week, the Financial Times reported, citing people familiar with the matter.

AstraZeneca may resume halted COVID-19 vaccine trial next week: report

The vaccine race frontrunners have paused late-stage trials after a "suspected serious adverse reaction" in one British participant.

AstraZeneca, Oxford COVID-19 Vaccine Efforts Suffer Setback

Dow Jones Industrial Average futures are trying to erase some of their losses after an intense sell-off experienced on Wall Street yesterday.

Stock Market: Dow Soars 600 Points; Nasdaq Moves Higher Despite AstraZeneca Coronavirus Vaccine News

BioNTech SE

GlaxoSmithKline

Johnson & Johnson

Merck

Novavax

The COVID-19 vaccine developers pledge to observe high ethical standards and sound scientific principles in conducting clinical studies and manufacturing of vaccines.

CEOs of Nine Coronavirus Vaccine Makers Sign Safety Pledge

Amid rising optimism on timely approval of a safe vaccine,  the vaccine development efforts of AstraZeneca (AZN) have hit a roadblock.

Coronavirus Vaccine Efforts Hit as AstraZeneca Halts Study

South African volunteers on AstraZeneca's experimental coronavirus vaccine trial said they were not worried to hear the trial had been paused after a participant fell ill and they hoped to be part of a potential solution to the pandemic.

South African volunteers on AstraZeneca vaccine trial say not alarmed by pause

The comments came a day after pharmaceutical giant AstraZeneca said it was pausing its late-stage Covid-19 vaccine clinical trial after a study participant  is suspected of developing a serious adverse reaction to the drug.

Fauci Says AstraZeneca Pause ‘Unfortunate’, WHO Stresses Safety Over Speed In Race For Covid-19 Vaccine

A large phase 3 trial for the drugmaker's COVID-19 vaccine has been put on hold.

Why AstraZeneca Briefly Lost $11.3 Billion in Market Capitalization

Coronavirus vaccine company stocks rose Wednesday after AstraZeneca paused a late-stage trial when one participant got ill.
The post Coronavirus Vaccine Developers Jump As Rival AstraZeneca Pauses Trials appeared first on Investor's Business Daily.

Coronavirus Vaccine Developers Jump As Rival AstraZeneca Pauses Trials

In an announcement on late Tuesday, AstraZeneca plc (LON: AZN) said that late-stage trial for its candidate COVID-19 vaccine had been paused after a study participant met with an unexplained severe adverse reaction. AstraZeneca’s experimental vaccine was among the top candidates of a potential cure for the novel flu-like virus.

AstraZeneca halts late-stage trial for its candidate COVID-19 vaccine

AstraZeneca has suspended global trials of its experimental coronavirus vaccine after an unexplained illness in a participant, knocking the British drugmaker's shares on Wednesday as prospects for an early rollout dimmed.

AstraZeneca pauses coronavirus vaccine trial, shares slip on rollout doubts

Safety of a prospective COVID-19 vaccine comes "first and foremost", the World Health Organization's chief scientist said on Wednesday, as a trial of a leading candidate from AstraZeneca was paused due to concerns over side effects.

News for AstraZeneca Stock (AZN)